Alcon Inc

Alcon Inc. is a global eye care company that develops, manufactures, and markets a broad portfolio of surgical and vision care products. The Surgical segment includes intraocular lenses (IOLs) for cataract surgery, consumables used in ophthalmic procedures, surgical equipment such as the Unity phacoemulsification platform, and devices for vitreoretinal, refractive laser, and glaucoma surgery. The Vision Care segment encompasses daily disposable, reusable, and color-enhancing contact lenses, cell therapies to treat ocular diseases, and a comprehensive portfolio of ocular health products including the Systane and Tryptyr dry eye product lines, ocular allergy treatments, glaucoma products, contact lens care solutions, ocular vitamins, and redness relievers. Alcon's products serve eye care professionals and patients in over 140 countries, addressing conditions such as cataracts, glaucoma, retinal diseases, refractive errors, and dry eye disease. The company employs more than 25,000 associates and is dual-listed on the SIX Swiss Exchange and the New York Stock Exchange. Alcon holds a 21.4% voting interest in an associated company and maintains strategic investments in early-stage ophthalmic technology companies including the 2025 acquisitions of Aurion Biotech (corneal cell therapy), Cylite (diagnostic devices), and LumiThera (photobiomodulation for dry age-related macular degeneration). Updated Aug 10, 2026